Trade HOOKIPA Pharma Inc. - HOOK CFD

Add to favourite

0.7302

3.69%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.0165

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

HOOKIPA Pharma Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	0.7582
Open*	0.7482
1-Year Change*	3.13%
Day's Range*	0.7106 - 0.7532
52 wk Range	0.41-2.05
Average Volume (10 days)	678.72K
Average Volume (3 months)	51.56M
Market Cap	55.90M
P/E Ratio	-100.00K
Shares Outstanding	83.95M
Revenue	20.55M
EPS	-0.99
Dividend (Yield %)	N/A
Beta	0.98
Next Earnings Date	Mar 13, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	0.7582	-0.0020	-0.26%	0.7602	0.7882	0.7482
Apr 17, 2024	0.7607	-0.0475	-5.88%	0.8082	0.8082	0.7392
Apr 16, 2024	0.7851	0.0368	4.92%	0.7483	0.8051	0.7282
Apr 15, 2024	0.7385	-0.0297	-3.87%	0.7682	0.8382	0.7282
Apr 12, 2024	0.7845	-0.0237	-2.93%	0.8082	0.8282	0.7102
Apr 11, 2024	0.8034	0.0252	3.24%	0.7782	0.8267	0.7782
Apr 10, 2024	0.8182	-0.0257	-3.05%	0.8439	0.8439	0.7982
Apr 9, 2024	0.8282	-0.0300	-3.50%	0.8582	0.8892	0.8183
Apr 8, 2024	0.8382	0.0700	9.11%	0.7682	0.8631	0.7382
Apr 5, 2024	0.7381	0.0077	1.05%	0.7304	0.7437	0.7004
Apr 4, 2024	0.7434	-0.0148	-1.95%	0.7582	0.7762	0.7382
Apr 3, 2024	0.7672	0.0390	5.36%	0.7282	0.7757	0.7282
Apr 2, 2024	0.7482	0.0300	4.18%	0.7182	0.7572	0.6992
Apr 1, 2024	0.7096	0.0014	0.20%	0.7082	0.7282	0.7082
Mar 28, 2024	0.7102	-0.0090	-1.25%	0.7192	0.7333	0.7082
Mar 27, 2024	0.7182	0.0200	2.86%	0.6982	0.7252	0.6982
Mar 26, 2024	0.7162	0.0130	1.85%	0.7032	0.7182	0.6982
Mar 25, 2024	0.6982	-0.0250	-3.46%	0.7232	0.7282	0.6930
Mar 22, 2024	0.7092	-0.0291	-3.94%	0.7383	0.7383	0.7091
Mar 21, 2024	0.7222	0.0192	2.73%	0.7030	0.7283	0.7030

HOOKIPA Pharma Inc. Events

Time (UTC)	Country	Event
Thursday, April 25, 2024
Time (UTC) 12:00	Country US	Event HOOKIPA Pharma Inc HB-200 Phase 2/3 Clinical Trial Update HOOKIPA Pharma Inc HB-200 Phase 2/3 Clinical Trial Update Forecast - Previous -
Thursday, May 9, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 HOOKIPA Pharma Inc Earnings Release Q1 2024 HOOKIPA Pharma Inc Earnings Release Forecast - Previous -
Friday, June 7, 2024
Time (UTC) 14:00	Country US	Event HOOKIPA Pharma Inc Annual Shareholders Meeting HOOKIPA Pharma Inc Annual Shareholders Meeting Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	14.249	18.448	19.584	11.942	7.629
Revenue	14.249	18.448	19.584	11.942	7.629
Total Operating Expense	87.404	100.122	72.869	63.027	28.809
Selling/General/Admin. Expenses, Total	20.189	19.172	19.715	17.809	6.844
Research & Development	67.126	80.518	52.738	44.854	21.965
Operating Income	-73.155	-81.674	-53.285	-51.085	-21.18
Interest Income (Expense), Net Non-Operating	0.946	-0.871	-0.386	0.71	-0.778
Other, Net	7.524	6.881	9.589	7.338	5.745
Net Income Before Taxes	-64.685	-75.664	-44.082	-43.037	-16.213
Net Income After Taxes	-64.915	-75.665	-44.082	-43.037	-16.237
Net Income Before Extra. Items	-64.915	-75.665	-44.082	-43.037	-16.237
Net Income	-64.915	-75.665	-44.082	-43.037	-16.237
Income Available to Common Excl. Extra. Items	-64.915	-75.665	-44.082	-43.037	-16.237
Income Available to Common Incl. Extra. Items	-64.915	-75.665	-44.082	-43.037	-16.237
Diluted Net Income	-64.915	-75.665	-44.082	-43.037	-16.237
Diluted Weighted Average Shares	65.513	32.8336	26.0391	25.5661	25.4085
Diluted EPS Excluding Extraordinary Items	-0.99087	-2.3045	-1.69292	-1.68336	-0.63904
Dividends per Share - Common Stock Primary Issue					0
Diluted Normalized EPS	-0.99087	-2.3045	-1.69292	-1.68336	-0.63904
Depreciation / Amortization	0.089	0.432	0.416	0.364

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	2.679	3.176	7.828	2.23	2.746
Revenue	2.679	3.176	7.828	2.23	2.746
Total Operating Expense	24.151	25.833	21.416	23.223	21.173
Selling/General/Admin. Expenses, Total	4.445	4.902	3.824	4.937	5.026
Research & Development	19.706	20.931	17.592	18.286	16.147
Operating Income	-21.472	-22.657	-13.588	-20.993	-18.427
Interest Income (Expense), Net Non-Operating	1.214	1.049	0.801	0.43	-0.049
Other, Net	2.242	2.133	0.705	2.283	2.121
Net Income Before Taxes	-18.016	-19.475	-12.082	-18.28	-16.355
Net Income After Taxes	-18.016	-19.68	-12.311	-18.28	-16.356
Net Income Before Extra. Items	-18.016	-19.68	-12.311	-18.28	-16.356
Net Income	-18.016	-19.68	-12.311	-18.28	-16.356
Income Available to Common Excl. Extra. Items	-18.016	-19.68	-12.311	-18.28	-16.356
Income Available to Common Incl. Extra. Items	-18.016	-19.68	-12.311	-18.28	-16.356
Diluted Net Income	-18.016	-19.68	-12.311	-18.28	-16.356
Diluted Weighted Average Shares	82.7053	54.7208	65.513	54.7337	54.698
Diluted EPS Excluding Extraordinary Items	-0.21783	-0.35964	-0.18792	-0.33398	-0.29902
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.21783	-0.35964	-0.18792	-0.33398	-0.29902

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	147.196	102.135	171.504	128.017	62.311
Cash and Short Term Investments	112.488	65.921	142.743	113.151	48.58
Cash & Equivalents	112.488	65.921	142.743	113.151	48.58
Total Receivables, Net	22.012	21.166	20.657	9.727	4.919
Accounts Receivable - Trade, Net	6.533	6.895	5.542	1.537	4.919
Prepaid Expenses	12.159	14.482	8.104	5.139	8.812
Total Assets	170.454	126.045	187.817	143.745	68.251
Property/Plant/Equipment, Total - Net	21.976	22.115	13.969	14.603	4.337
Property/Plant/Equipment, Total - Gross	29.755	28.481	19.066	18.049	6.403
Accumulated Depreciation, Total	-7.779	-6.366	-5.097	-3.446	-2.066
Other Long Term Assets, Total	1.282	1.795	2.344	1.125	1.603
Total Current Liabilities	35.632	27.654	21.143	14.755	14.695
Accounts Payable	5.488	8.762	8.009	0.944	3.656
Accrued Expenses	12.069	9.598	7.138	5.262	4.42
Notes Payable/Short Term Debt	0	0	0	1.224	0
Other Current Liabilities, Total	16.481	6.481	5.841	7.166	6.619
Total Liabilities	67.937	36.453	31.694	25.846	23.852
Total Long Term Debt	0.911	2.219	4.795	3.862	4.392
Long Term Debt	0.911	2.219	4.537	3.495	4.392
Other Liabilities, Total	31.394	6.58	5.756	7.229	4.765
Total Equity	102.517	89.592	156.123	117.899	44.399
Redeemable Preferred Stock				0	104.774
Common Stock	0.005	0.003	0.003	0.003	0
Additional Paid-In Capital	397.349	317.135	309.288	225.568	3.327
Retained Earnings (Accumulated Deficit)	-287.681	-222.766	-147.101	-103.019	-59.982
Other Equity, Total	-7.156	-4.78	-6.067	-4.653	-3.72
Total Liabilities & Shareholders’ Equity	170.454	126.045	187.817	143.745	68.251
Total Common Shares Outstanding	54.7167	31.2032	29.7684	25.5661	25.4085
Current Port. of LT Debt/Capital Leases	1.594	2.813	0.155	0.159
Capital Lease Obligations	0	0	0.258	0.367
Preferred Stock - Non Redeemable, Net			0
Other Current Assets, Total	0.537	0.566

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	139.471	168.143	139.913	147.196	129.611
Cash and Short Term Investments	107.676	135.587	109.6	112.488	99.776
Cash & Equivalents	107.676	135.587	109.6	112.488	99.776
Total Receivables, Net	23.05	20.461	18.463	22.012	12.045
Accounts Receivable - Trade, Net	0.675	0.255	0.501	6.533	0.743
Prepaid Expenses	8.745	12.095	11.85	12.159	17.3
Total Assets	164.01	191.11	163.088	170.454	151.526
Property/Plant/Equipment, Total - Net	23.029	21.54	21.661	21.976	20.553
Other Long Term Assets, Total	1.51	1.427	1.514	1.282	1.362
Total Current Liabilities	40.576	46.245	44.209	35.632	26.052
Accounts Payable	8.929	11.645	7.075	5.488	7.824
Accrued Expenses	14.054	13.215	15.012	12.069	8.757
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	1.026	1.012	2.067	1.594	1.393
Other Current Liabilities, Total	16.567	20.373	20.055	16.481	8.078
Total Liabilities	68.959	78.78	79.609	67.937	38.178
Total Long Term Debt	0	0	0	0.911	2.4
Long Term Debt	0	0	0	0.911	0.8
Capital Lease Obligations				0	1.6
Other Liabilities, Total	28.383	32.535	35.4	31.394	9.726
Total Equity	95.051	112.33	83.479	102.517	113.348
Preferred Stock - Non Redeemable, Net		0
Common Stock	0.008	0.008	0.005	0.005	0.005
Additional Paid-In Capital	445.512	444.941	398.008	397.349	396.348
Retained Earnings (Accumulated Deficit)	-344.443	-325.377	-307.361	-287.681	-275.37
Other Equity, Total	-6.026	-7.242	-7.173	-7.156	-7.635
Total Liabilities & Shareholders’ Equity	164.01	191.11	163.088	170.454	151.526
Total Common Shares Outstanding	83.9501	83.9501	54.7223	54.7167	54.7167
Property/Plant/Equipment, Total - Gross	32.019	30.466	30.089	29.755	27.207
Accumulated Depreciation, Total	-8.99	-8.926	-8.428	-7.779	-6.654
Other Current Assets, Total	0	0	0	0.537	0.49

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-64.915	-75.665	-44.082	-43.037	-16.237
Cash From Operating Activities	-19.997	-66.016	-39.339	-41.731	-14.998
Cash From Operating Activities	3.602	4.64	4.15	1.443	0.64
Non-Cash Items	5.203	8.87	8.71	7.241	0.874
Cash Taxes Paid	0.001	0.001	0	0	0.024
Cash Interest Paid	0.032	0.048	0.097	0.064	0.071
Changes in Working Capital	36.113	-3.861	-8.117	-7.378	-0.275
Cash From Investing Activities	-5.017	-12.581	-2.371	-1.999	-2.15
Capital Expenditures	-5.017	-12.581	-2.371	-1.999	-2.15
Cash From Financing Activities	72.271	-0.235	73.42	109.751	6.873
Issuance (Retirement) of Stock, Net	75.316	0.203	75.063	112.03	6.864
Issuance (Retirement) of Debt, Net	-2.85	-0.438	-1.419	-2.279	0.009
Foreign Exchange Effects	-0.725	2.567	-2.108	-1.026	-2.507
Net Change in Cash	46.532	-76.265	29.602	64.995	-12.782
Financing Cash Flow Items	-0.195	0	-0.224

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-19.68	-64.915	-52.604	-34.324	-17.968
Cash From Operating Activities	-2.848	-19.997	-33.134	-16.626	1.733
Cash From Operating Activities	0.921	3.602	2.698	1.938	1.078
Non-Cash Items	0.662	5.203	4.03	3.158	1.695
Cash Taxes Paid	0	0.001	0.001	0.001	0
Cash Interest Paid	0.001	0.032	0.021	0.022	0
Changes in Working Capital	15.249	36.113	12.742	12.602	16.928
Cash From Investing Activities	-0.274	-5.017	-4.418	-3.46	-1.828
Capital Expenditures	-0.274	-5.017	-4.418	-3.46	-1.828
Cash From Financing Activities	-0.735	72.271	72.467	72.34	75.293
Issuance (Retirement) of Stock, Net	0.001	75.316	75.316	75.314	75.313
Issuance (Retirement) of Debt, Net	-0.597	-2.85	-2.849	-2.974	-0.02
Foreign Exchange Effects	0.434	-0.725	-1.151	-0.307	-0.307
Net Change in Cash	-3.423	46.532	33.764	51.947	74.891
Financing Cash Flow Items	-0.139	-0.195

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

HOOKIPA Pharma Inc. Company profile

About Hookipa Pharma Inc

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company develops immunotherapeutics based on its arenavirus platform that are designed to target and amplify a T cell and immune response to disease. The Company's infectious and oncology product candidates HB-101, HB-201, HB-202 and HB-300. The infectious disease product candidate, HB-101, is in a randomized, double-blinded Phase II clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of human papillomavirus-positive cancers. The Company is developing its self-antigen project in this area, HB-300, as a replicating technology-based product candidate in metastatic, hormone-resistant prostate cancer.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Hookipa Pharma Inc revenues increased 1% to $14.6M. Net loss increased 72% to $54.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 60% to $58M (expense), Other income and expenses, net decrease from $1.6M (income) to $1.3M (expense).

Industry:

Pharmaceuticals (NEC)

The Empire State Building
350 Fifth Avenue, Room/Suite 7240
NEW YORK
NEW YORK 10118
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024